Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Dermatologic 1

Conditions

Keratosis, Actinic 5Skin Diseases 1Precancerous Conditions 1Keratosis 1Hutchinson's Melanotic Freckle 1Carcinoma, Basal Cell 1

Interventions

Biopsy 8Polymerase Chain Reaction 6Peripheral Blood Stem Cell Transplantation 5Epoetin Alfa 5Sulindac 4Microarray Analysis 4Gene Expression Profiling 4Cyclophosphamide 4Colposcopy 4Cetuximab 4Celecoxib 4fludarabine phosphate 3Vaginal Smears 3Selenium 3Methotrexate 3Imiquimod 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3Eflornithine 3Darbepoetin alfa 3Aspirin 3Antilymphocyte Serum 3Whole-Body Irradiation 2Vitamin E 2Tacrolimus 2Radiotherapy, Intensity-Modulated 2Methylprednisolone 2Light Coagulation 2Interferon-alpha 2In Situ Hybridization, Fluorescence 2Immunohistochemistry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Precancerous Conditions × BF-200 ALA × Clear all
NCT05060237 2024-10-17

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Biofrontera Bioscience GmbH

Phase 1 Completed
112 enrolled 21 charts
DermatologicOther neoplasm

Keratosis, Precancerous Conditions, Skin Diseases, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡